Application of a calcitriol-functionalized injectable hydrogel in the preparation of dressings for treating diabetic foot ulcers
By using calcitriol-functionalized injectable hydrogels for UV cross-linking, the problem of inconsistent local delivery of vitamin D in diabetic foot ulcers has been solved, achieving effective wound healing and biocompatibility, and making it suitable for irregular wounds.
Patent Information
- Application Number
- CN202611178951.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-05
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2046-08-05
AI Technical Summary
Existing treatment strategies are not effective in promoting the healing of diabetic foot ulcers, especially because the local delivery of vitamin D is not continuous, making the wound difficult to heal. Furthermore, existing dressings are not suitable for irregular and potentially deep DFU wounds.
The calcitriol-functionalized injectable hydrogel, which forms a porous dressing through ultraviolet light cross-linking, enables continuous and effective delivery of calcitriol at the wound site, regulating inflammatory responses, promoting wound re-epithelialization, and angiogenesis.
It significantly promotes wound healing, maintains a moist wound environment, reduces biosafety risks, has good compatibility, is easy to operate, and can continuously exert the therapeutic effect of calcitriol, making it suitable for irregular wounds.
Smart Images

Figure CN122665182B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, and in particular to the application of a calcitriol-functionalized injectable hydrogel in the preparation of dressings for the treatment of diabetic foot ulcers. Background Technology
[0002] Diabetic foot ulcer (DFU) is one of the most serious chronic complications of diabetes. Its development is closely related to long-term hyperglycemia, chronic inflammation, vascular disease, neuropathy, and impaired local repair cell function. Diabetic wounds often exhibit prolonged inflammatory responses, impaired proliferation and migration of keratinocytes and fibroblasts, insufficient angiogenesis, reduced collagen deposition, and delayed reepithelialization, leading to poor wound healing and increased risks of infection, amputation, and death. Current treatment strategies mainly focus on local wound debridement, decompression, anti-infection, improving blood circulation, and dressing management. While these can improve the prognosis of some patients, they are still insufficient to effectively promote local healing of diabetic wounds. Ordinary wounds heal through the body's self-healing process; however, the pathological microenvironment of DFU wounds hinders the normal healing process, resulting in slow healing or even non-healing of DFU wounds. Existing strategies are insufficient to meet the treatment needs of DFU.
[0003] Vitamin D is a fat-soluble steroid hormone with broad biological activity. The main route of vitamin D acquisition in the human body is through the synthesis of cholecalciferol (vitamin D3) in the skin under ultraviolet radiation, followed by dietary or supplemental intake. Vitamin D3 is catalyzed by hepatic 25-hydroxylase to produce 25-hydroxyvitamin D, which is the main serological indicator for assessing the body's vitamin D nutritional status. 25-hydroxyvitamin D is then converted into biologically active 1,25-dihydroxyvitamin D, or calcitriol, by renal 1α-hydroxylase. Calcitriol exerts its biological effects by binding to vitamin D receptors (VDRs), which are widely distributed in various tissues and cells of the human body. In addition to its classic roles in calcium and phosphorus metabolism and bone homeostasis regulation, the vitamin D / VDR signaling pathway also participates in immune regulation, cell proliferation and differentiation, inflammatory response regulation, and the maintenance of oxidative stress homeostasis. These non-classical functions make it a focus of research in the prevention and treatment of various chronic diseases.
[0004] Currently, vitamin D preparations are generally administered orally. The inventors have demonstrated through use that oral vitamin D3 preparations can promote wound healing and epidermal regeneration in diabetic foot ulcers, but there is still significant room for improvement in the duration of these effects. US patent application US2018000980A1 discloses a wound dressing containing vitamin D or its analogues or metabolites; however, this dressing is intended for surgical site infections. Its principle is to increase the local expression and secretion of LL-37 and other beneficial substances (including antimicrobial peptides) at or near the site of the composition by locally delivering vitamin D or its analogues or metabolites. This dressing is a pre-formed dressing and is not suitable for irregular and potentially deep DFU wounds, sinus tracts, and fistulas.
[0005] Therefore, achieving continuous and effective local delivery of vitamin D to DFU wounds is a significant challenge for clinical translation. Summary of the Invention
[0006] The purpose of this invention is to provide an application of calcitriol-functionalized injectable hydrogel in the preparation of dressings for treating diabetic foot ulcers, in order to solve the above-mentioned problems.
[0007] To achieve the above objectives, the technical solution adopted by the present invention is as follows:
[0008] Application of a calcitriol-functionalized injectable hydrogel in the preparation of dressings for the treatment of diabetic foot ulcers.
[0009] As a preferred technical solution, the preparation method of the calcitriol-functionalized injectable hydrogel is as follows:
[0010] (1) Dissolve the methacrylated macromolecule in pure water or phosphate buffer to obtain MamoleMA solution, and then add the photoinitiator solution to the MamoleMA solution to obtain gel precursor solution;
[0011] (2) Dissolve calcitriol in a solubilizer to obtain calcitriol mother liquor;
[0012] (3) Add the calcitriol mother liquor obtained in step (2) to the gel precursor solution obtained in step (1), mix evenly to obtain a mixture; then add a photoinitiator and crosslink with ultraviolet light to form calcitriol functionalized hydrogel.
[0013] As a further preferred technical solution, in step (1), the macromolecule in the methacrylated macromolecule is selected from one of alginic acid, hyaluronic acid, chitosan, dextran, cellulose, gelatin and silk fibroin.
[0014] As a further preferred technical solution, the macromolecule in the methacrylated macromolecule is gelatin.
[0015] As a preferred technical solution, in step (1), the concentration of the methacrylated macromolecular solution is 2-20 wt%.
[0016] As a preferred technical solution, in step (2), the solubilizer is selected from one of glycerol, triglycerides, propylene glycol, dimethyl sulfoxide, ethyl acetate and polyethylene glycol.
[0017] As a preferred technical solution, in step (3), the photoinitiator is selected from 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone (hereinafter referred to as "I2959") and lithium phenyl-2,4,6-trimethylbenzoylphosphonate (hereinafter referred to as "LAP").
[0018] As a preferred technical solution, in step (3), the mass of the added photoinitiator is 0.01%-0.5% of the volume of the mixed liquid.
[0019] As a preferred technical solution, in step (3), the wavelength of the ultraviolet light is 365 nm-405 nm and the intensity is 5-100 mW / cm. 2 The irradiation time is 1-120 seconds.
[0020] As a preferred technical solution, the concentration of calcitriol in the calcitriol functionalized hydrogel is 1-500 nmol / L.
[0021] Compared with the prior art, the advantages of the present invention are as follows:
[0022] (1) Significant effect: The calcitriol functionalized hydrogel dressing provided by the present invention has rich biological activities such as regulating inflammatory response, local anti-infection, promoting wound re-epithelialization, granulation tissue formation and angiogenesis, which helps to effectively repair wounds, especially DFU wounds; compared with US2018000980A1, the dressing of the present invention is a gel formulation, which is more conducive to maintaining the moist environment of the wound, thereby promoting wound healing.
[0023] (2) Good continuity and high biosafety: The hydrogel dressing provided by the present invention can achieve continuous and effective delivery of calcitriol to the wound, especially the DFU wound, thereby maximizing the therapeutic effect of calcitriol and reducing the biosafety risk of local high-dose vitamin D.
[0024] (3) Good controllability of degradation: The hydrogel dressing provided by the present invention can adjust the degradation of the material by adjusting the raw material content and light curing time, so as to adapt to different wound repair needs.
[0025] (4) Convenient operation and good compatibility: The precursor solution of this material can be stored at low temperature and has good injectability at room temperature. After being injected into the wound, it can form a stable hydrogel after a short period of ultraviolet light irradiation, which has excellent compatibility with irregular wound surfaces. Attached Figure Description
[0026] Figure 1 These are scanning electron microscope images of the calcitriol-functionalized hydrogel dressing prepared in Example 1;
[0027] Figure 2 The vitamin D release curve of the calcitriol-functionalized hydrogel dressing prepared in Example 1;
[0028] Figure 3 These are scanning electron microscope images of the calcitriol-functionalized hydrogel dressing prepared in Example 3;
[0029] Figure 4 These are rheological frequency scan images of the calcitriol-functionalized hydrogel dressing prepared in Example 3;
[0030] Figure 5 The cyclic stress-strain curve of the calcitriol-functionalized hydrogel dressing prepared in Example 3 is shown.
[0031] Figure 6 These are scanning electron microscope images of the calcitriol-functionalized hydrogel dressing prepared in Example 5 before and after hemostasis;
[0032] Figure 7 The effects of different treatments in Example 6 on wound healing in diabetic rats;
[0033] Figure 8 The effect of different treatments on wound thickness in diabetic rats in Example 6;
[0034] Figure 9 The effect of different treatments on the proportion of PCNA-positive cells in the wounds of diabetic rats in Example 6;
[0035] Figure 10 The effects of different treatments in Example 6 on M2 macrophages in the wound of diabetic rats;
[0036] Figure 11 The effects of different treatments in Example 6 on VDR levels in wound tissue of diabetic rats;
[0037] Figure 12 The effects of different treatments in Example 6 on MAPK-ERK1 / 2 signaling pathway-related proteins in rat wound tissue 10 days after wound diagnosis;
[0038] Figure 13The effect of calcitriol-loaded GelMA hydrogel on wound healing rate in diabetic rats in Example 7;
[0039] Figure 14 The effect of calcitriol-loaded GelMA hydrogel on wound thickness in diabetic rats in Example 7;
[0040] Figure 15 The effect of calcitriol-loaded GelMA hydrogel on collagen tissue in wounds of diabetic rats in Example 7;
[0041] Figure 16 The effect of calcitriol-loaded GelMA hydrogel on dermal microvessel density in wounds of diabetic rats in Example 7;
[0042] Figure 17 The effect of calcitriol-loaded GelMA hydrogel on the proportion of PCNA-positive cells in the wound of diabetic rats in Example 7;
[0043] Figure 18 The effect of calcitriol-loaded GelMA hydrogel on M1 macrophages in the wound of diabetic rats in Example 7;
[0044] Figure 19 The effect of calcitriol-loaded GelMA hydrogel on M2 macrophages in the wound of diabetic rats in Example 7. Detailed Implementation
[0045] To explain the technical content, objectives, and effects of the present invention in detail, the following specific embodiments are provided to further illustrate the content of the present invention. However, the content of the present invention is far more than the following examples.
[0046] Example 1
[0047] A calcitriol-functionalized injectable hydrogel dressing, the preparation method of which is as follows:
[0048] (1) Dissolve 0.8 g of methacrylated gelatin (GelMA) (purchased from Suzhou Yongqinquan Intelligent Equipment Co., Ltd.) in 10 mL of pure water to obtain a GelMA solution; then add 0.25% (w / v) lithium phenyl-2,4,6-trimethylbenzoylphosphonate (LAP) to the GelMA solution to obtain a gel precursor solution;
[0049] (2) Calcitriol was dissolved in dimethyl sulfoxide to obtain a concentration of 1×10 -3 Calcitriol stock solution (mol / L);
[0050] (3) Add 5 μL of the calcitriol mother liquor obtained in step (2) to 10 mL of the gel precursor solution obtained in step (1), and use a portable curing UV light source (405 nm, 25 mW / cm²) for curing. 2 Irradiate for 90 seconds to allow it to fully cross-link into a gel, thus obtaining a hydrogel;
[0051] The obtained hydrogel dressing has a porous structure, as shown in the scanning electron microscope. Figure 1 As shown, it can effectively absorb exudate from the wound. Furthermore, it can continuously release calcitriol for up to 48 hours to achieve a sustained therapeutic effect, such as... Figure 2 As shown. Figure 2 It is 1cm 3 The hydrogel was immersed in 5 mL of PBS, and 2 mL of PBS was taken out at each time point to measure and calculate the release of calcitriol.
[0052] Example 2
[0053] A calcitriol-functionalized injectable hydrogel dressing, the preparation method of which is as follows:
[0054] (1) Dissolve 0.6 g GelMA in 10 mL of pure water, and then add 0.20% (w / v) LAP to the GelMA solution to obtain a gel precursor solution;
[0055] (2) Dissolve calcitriol in glycerol to obtain a concentration of 1×10 -5 Calcitriol stock solution (mol / L);
[0056] (3) Add 200 μL of calcitriol stock solution to 10 mL of gel precursor solution, and use a portable curing UV light source (405 nm, 50 mW / cm²) for curing. 2 Irradiate for 60 seconds to allow it to fully cross-link into a gel, and you will get the product.
[0057] Example 3
[0058] (1) Dissolve 0.9 g GelMA and 0.1 g methacrylated hyaluronic acid (HAMA) in 10 mL phosphate buffer, and then add 0.25% (w / v) 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone (I2959) to obtain a gel precursor solution;
[0059] (2) Dissolve calcitriol in glycerol to obtain a concentration of 1×10 -6 mol / L of mother liquor;
[0060] (3) Add 100 μL of calcitriol stock solution to 10 mL of gel precursor solution, and use a portable curing UV light source (405 nm, 50 mW / cm²) for curing. 2 Irradiate for 120 seconds to allow it to fully cross-link into a gel, and you will get the product.
[0061] Scanning electron micrograph of the obtained gel dressing is shown below. Figure 3 As shown, it has a porous structure, which can effectively absorb exudate from the wound.
[0062] Frequency scanning curve as shown Figure 4 As shown, this indicates that it possesses good mechanical properties and can resist the influence of external frequency changes: the cyclic stress-strain curve is as follows. Figure 5 As shown, it demonstrates good fatigue stability and can be used on wounds in moving parts of the body.
[0063] Example 4
[0064] A calcitriol-functionalized injectable hydrogel dressing, the preparation method of which is as follows:
[0065] (1) Dissolve 0.6 g GelMA in 10 mL of pure water, and then add 0.25% (w / v) LAP to obtain a gel precursor solution;
[0066] (2) Dissolve calcitriol in propylene glycol to obtain a calcitriol mother liquor with a concentration of 1×10-4 mol / L;
[0067] (3) Add 30 μL of calcitriol stock solution to 10 mL of gel precursor solution, and use a portable curing UV light source (405 nm, 50 mW / cm²) for curing. 2 Irradiate for 90 seconds to allow it to fully cross-link into a gel, and you will get the product.
[0068] Example 5
[0069] A calcitriol-functionalized injectable hydrogel dressing, the preparation method of which is as follows:
[0070] (1) Dissolve 2.0 g of sodium alginate methacrylate (AlgMA) in 10 mL of pure water, and then add 0.25% (w / v) LAP to obtain a gel precursor solution;
[0071] (2) Dissolve calcitriol in dimethyl sulfoxide to obtain a calcitriol mother liquor with a concentration of 1×10-4 mol / L;
[0072] (3) Add 50 μL of calcitriol stock solution to 10 mL of gel precursor solution, and use a portable curing UV light source (405 nm, 50 mW / cm²) for curing. 2Irradiate for 100 seconds to allow it to fully cross-link into a gel, and you will get the product.
[0073] The obtained gel dressing can effectively promote platelet adhesion, thus exhibiting good hemostatic properties. Figure 6 ).
[0074] Example 6
[0075] Effect verification test
[0076] 1. Establishment and validation of a diabetic rat model in SD rats
[0077] 1.1 A diabetic rat model was established in SD rats by combining a high-sugar, high-fat diet with intraperitoneal injection of streptozotocin (STZ). The specific method was as follows:
[0078] (1) Sixty 4-week-old male SD rats, weighing 100-150g, clean grade, not castrated, were selected and housed in the Animal Experiment Center of West China Hospital, Sichuan University (4 rats / cage). The rats were kept under 12 hours of light and 12 hours of darkness daily, with the room temperature maintained at 18-22℃. The room and cages were disinfected regularly. Considering the possibility of model failure, death during the breeding period, or general condition unsuitable for continuing the experiment, the number of animals was appropriately increased at the beginning of the experiment. All rats were acclimatized for 1 week, during which they were allowed free access to water and food, and their mental state, activity level, coat color, food intake and water intake were observed regularly.
[0079] After the adaptation period, rats were randomly divided into a healthy control group (Health) and a diabetic model group (Diabetes). Fourteen rats were included in the healthy control group and fed a normal diet; 46 rats were included in the diabetic model group and fed a high-sugar, high-fat diet. The rats were fed for 4 weeks, and their random blood glucose and body weight were measured every 2 weeks during the feeding period.
[0080] (2) Preparation of citrate buffer
[0081] Prepare fresh citrate buffer solution on the day of streptozotocin injection. Weigh 1.890 g of citric acid and 2.646 g of sodium citrate, and place them in two clean 100 mL glass bottles. Add 90 mL of pure water to each bottle and dissolve thoroughly. Then, take 85 mL of each solution and mix them into a new 200 mL glass bottle. Use pH test strips to check the pH of the buffer solution and adjust the pH to 4.2–4.5. If the pH is too low, add an appropriate amount of sodium citrate solution; if the pH is too high, add an appropriate amount of citric acid solution. Store the prepared buffer solution in an icebox for later use.
[0082] (3) Preparation of streptozotocin solution
[0083] Streptozotocin powder was rapidly weighed and dispensed into 10 mL clean EP tubes (70 mg / tube, approximately the dosage for one rat cage) under light-protected conditions. The EP tubes were wrapped in aluminum foil, sealed in a resealable bag, and stored at -20 °C. On the day of injection, the dispensed streptozotocin powder was removed, and 7 mL of freshly prepared citrate buffer was added to each tube to dissolve it, preparing a 10 mg / mL streptozotocin solution. After preparation, the solution was gently inverted to mix, and then filtered through a 0.22 μm filter before use. The streptozotocin solution was prepared fresh each time, and all preparation, filtration, and injection processes were conducted in the dark as much as possible, minimizing the operation time.
[0084] (4) Establishment of a diabetes model
[0085] After being fed a high-sugar, high-fat diet for 4 weeks, diabetic rats in the model group were fasted overnight before streptozotocin injection, but water intake was not restricted. On the day of injection, the weight of each rat was weighed and recorded, and the injection volume of streptozotocin was calculated based on the weight. The diabetic model group received an intraperitoneal injection of freshly prepared streptozotocin solution at a dose of 40 mg / kg. The healthy control group received an equal volume of citrate buffer filtered through a 0.22 μm filter via intraperitoneal injection. After the injection, the rats were returned to their cages and continued to be fed and given free access to water.
[0086] 1.2 Validation of the model using blood glucose and body weight:
[0087] During the first 4 weeks of a high-sugar, high-fat diet, the weight of both the diabetic and healthy rats showed a similar growth trend, while random blood glucose levels remained stable at normal levels. There were no significant differences in weight and blood glucose levels between the two groups.
[0088] Following intraperitoneal injection of STZ in week 4, random blood glucose levels in the diabetic group rats rapidly increased. By week 2 post-injection, their blood glucose levels were significantly higher than those in the normal group (P < 0.0001), and remained at a high level throughout the subsequent observation period (P < 0.0001). Simultaneously, weight gain in the diabetic group rats significantly stagnated after STZ injection, with their body weight significantly lower than that of the normally growing healthy group rats (P < 0.0001). At baseline, there were no significant differences in blood lipid and CRP levels between the healthy and diabetic groups. However, with high-fat, high-sugar feeding and the establishment of the diabetic model, blood lipid and CRP levels in the diabetic group rats gradually increased, reaching a significant level on the day of wound initiation (P < 0.05). Furthermore, during routine feeding, the diabetic group rats exhibited typical diabetic symptoms such as polydipsia, polyphagia, polyuria, dull and dry fur, and poor mental state.
[0089] The above findings, combined with the trends in blood glucose and body weight changes, indicate that this experiment successfully established a diabetic model in SD rats.
[0090] 1.3 Microstructure verification of the model:
[0091] On the day of creation, full-thickness skin tissue was collected from the backs of healthy and diabetic rats. HE staining, Masson staining, CD31 and PCNA immunohistochemical staining, and CD68 combined with CD80 / CD206 immunofluorescence staining were used to compare the skin microstructure, collagen deposition, microvascular density, cell proliferation activity, and macrophage polarization status of the two groups of rats. Results:
[0092] (1) HE staining results showed that on the day of trauma, the epidermis of the skin tissue of healthy rats was intact, the stratum corneum was clear, and the stratified squamous epithelial cells were arranged relatively neatly; the collagen fibers in the dermis were interlaced, and the structures of skin appendages such as hair follicles and sebaceous glands were visible; the subcutaneous fat layer and muscle layer were intact, and no obvious inflammatory cell infiltration or abnormal proliferation of fibrous tissue was observed. The skin tissue of diabetic rats also showed relatively intact epidermis, dermis and skin appendage structures under light microscopy, and no obvious necrosis, ulceration or obvious inflammatory cell infiltration was observed.
[0093] (2) Quantitative analysis of skin thickness was performed. The results showed that the epidermal thickness of rats in the diabetic group was significantly reduced compared with the healthy group, and the difference was statistically significant (P=0.0014). The dermal thickness of the diabetic group was also lower than that of the healthy group (P<0.0001). The comparison of full-thickness skin thickness was consistent with the above trend, and the full-thickness skin thickness of the diabetic group was significantly lower than that of the healthy group (P<0.0001).
[0094] (3) Masson staining was used to evaluate the distribution and deposition level of dermal collagen tissue in the skin of the two groups of rats. The results showed that the dermal collagen fibers in the healthy group were more densely arranged, while the arrangement and content of dermal collagen fibers in the diabetic group showed a decreasing trend. Quantitative analysis showed that the proportion of dermal collagen tissue in the diabetic group was lower than that in the healthy group, and the difference was statistically significant (P=0.0400).
[0095] (4) CD31 immunohistochemical staining was used to assess the density of dermal microvessels in the skin. The results showed that the density of CD31-positive microvessels in the skin tissue of diabetic rats was decreased compared with that in the healthy group, and the difference between the groups was statistically significant (P=0.0004). PCNA immunohistochemical staining was used to evaluate the proliferative activity of skin tissue cells. The results showed that the positive expression of PCNA in the skin tissue of diabetic rats was lower than that in the healthy group, and the difference was statistically significant (P=0.0009).
[0096] (5) Immunofluorescence staining with CD68 and CD80 / CD206 was used to compare the polarization status of macrophages in the two groups of skin tissue. CD68 / CD80 double-positive cell analysis showed that the number of M1 macrophages in the diabetic group was higher than that in the healthy group, and the difference was statistically significant (P<0.0001). CD68 / CD206 double-positive cell analysis showed no significant difference in the number of M2 macrophages between the diabetic group and the healthy group (P=0.2674).
[0097] 2. Effects of topical application of calcitriol and oral vitamin D on wound healing rate
[0098] This experiment further investigated the effects of vitamin D-related intervention on the wound healing process in a diabetic rat wound model.
[0099] 2.1 Experimental Methods:
[0100] Experimental groups included a health group, a diabetes control group, a topical calcitriol group, and an oral vitamin D3 group; the diabetes control group refers to the model group that did not receive any medication.
[0101] In animal experiments, the local calcitriol group received subcutaneous injection at the wound edge every other day; the oral vitamin D group (i.e., vitamin D3) received oral gavage every other day. The volume of medication was calculated based on the rat's body weight on the day of each gavage, and administered at a dose of 205.6 IU / kg. Within 4 days after wound incision, each group consisted of 12 rats; within 10 days, each group consisted of 9 rats; and on day 10 after wound incision, the remaining 3 rats from each group were observed until day 14.
[0102] 2.2 Experimental Results:
[0103] (1) Wound image acquisition
[0104] Wound observation and image acquisition were performed the day after incision. On Day 0, Day 2, Day 4, Day 6, Day 8, Day 10, Day 12, and Day 14, the wound was exposed under the same anesthesia conditions. The size, color, exudate, crusting, and condition of the surrounding skin were observed. The wound was photographed, maintaining a consistent distance, angle, and lighting conditions. After each photograph, a transparent film was used to cover the wound area, and the wound outline was traced along its edges. Excessive pressure or pulling on the wound edges was avoided during tracing to minimize the impact on the assessment of wound morphology and area. After tracing, the animal number, group, and time point were labeled on the film.
[0105] (2) Calculation of wound healing rate
[0106] The results of transparent film tracing at each time point were imported into ImageJ software for wound area measurement. Before measurement, a uniform scale was set, and the same standard was used as much as possible to identify the wound edge. The wound healing rate was calculated according to the following formula: Wound healing rate = (initial wound area - wound area at different times) / initial wound area
[44] . Wherein, the initial wound area is the wound area measured on Day 0, and the wound area at different time points is the wound area measured at the corresponding time point. By comparing the wound healing rates at different time points of each group, the effects of local calcitriol and oral vitamin D3 intervention on the healing of rat skin wounds were evaluated.
[0107] The results are as follows Figure 7 As shown, Figure 7 (A) Representative images of wound conditions at different times; (B) Wound healing rates at different times. Compared with the diabetic control group, the wound healing rate of the local calcitriol intervention group was significantly higher on day 2 (P<0.0001) and day 4 (P<0.0001) after wound creation. On day 6 after wound creation, the wound healing rate of the local calcitriol intervention group was still higher than that of the diabetic control group, and the difference was statistically significant (P=0.0023). By day 8 after wound creation, the wound healing rate of the local calcitriol intervention group was still higher than that of the diabetic control group (P=0.0482).
[0108] Compared with the diabetic control group, the oral vitamin D group showed a significantly higher wound healing rate on day 2 post-incision (P<0.0001) and a higher wound healing rate on day 4 post-incision (P=0.0006). On days 6 and 8 post-incision, the wound healing rate in the oral vitamin D group showed an increasing trend compared with the diabetic control group, but the difference was not statistically significant (day 6, P = 0.0924; day 8, P = 0.2714).
[0109] It is evident that diabetes primarily affects the early wound closure process, as evidenced by the lower wound healing rate in the diabetic control group compared to the healthy group in the early post-wound healing stage. Both local calcitriol intervention and oral vitamin D improved early wound closure in diabetic rats to some extent. The healing-promoting effect of the local calcitriol intervention group persisted until day 8 post-wound healing, while the improvement effect of the oral vitamin D group only lasted until day 4 post-wound healing. In other words, the hydrogel dressing of this invention, used for local intervention in DFU wounds, extends the duration of its healing effect on DFU wounds by twice that of conventional oral vitamin D.
[0110] 3. Effects of topical application of calcitriol and oral vitamin D on wound re-epithelialization and collagen deposition.
[0111] 3.1 Experimental Methods:
[0112] The experimental groups are the same as those in "2" above.
[0113] (1) Sampling of wound tissue
[0114] On the day of wound creation and at each scheduled sampling time, use clean surgical scissors to evenly cut the full-thickness skin tissue from the left and right sides of the back, either circular or near-circular, from the wound surface or its edges. Wound edge tissue refers to the full-thickness, near-circular tissue, including the center of the wound, the wound edges, and some surrounding normal skin, cut approximately 2 mm beyond the edge of the wound.
[0115] After washing the collected tissues from both sides with physiological saline, they were collected separately. The left skin tissue was cut in half along the diameter: one half was flattened as much as possible and placed in an embedding cassette, then fixed in 4% paraformaldehyde solution for subsequent paraffin embedding, sectioning, and histological examination; the other half was further divided into two equal parts, minced, and placed into two cryovials. The right skin tissue was directly divided into four parts along mutually perpendicular diameters, minced, and placed into four cryovials. All samples in the cryovials were labeled with the collection time, group, and sample number.
[0116] All samples were flash-frozen in liquid nitrogen immediately after collection and then transferred to a -80°C freezer for storage on the same day. Fixed tissue samples were thoroughly fixed in 4% paraformaldehyde and then used for subsequent dehydration, embedding, sectioning, and histopathological, immunohistochemical, or immunofluorescence assays.
[0117] (2) Hematoxylin-eosin (HE) staining and morphological measurement
[0118] A. Tissue processing and dewaxing: Tissue samples fixed with 4% paraformaldehyde were subjected to routine gradient dehydration, paraffin embedding, and sectioning. After baking, the sections were placed in dewaxing solution I and dewaxing solution II for 30 min each, followed by stepwise hydration with anhydrous ethanol, 95% ethanol, 85% ethanol, and 75% ethanol for 5 min each, and finally rinsed with running tap water for 5 min.
[0119] B. Staining procedure: Immerse the sections in hematoxylin staining solution for 5-10 min, rinse with running water until colorless; place in 1% hydrochloric acid ethanol solution for differentiation for about 3 s, wash with water; after blueing treatment with weakly alkaline aqueous solution, wash with water again; then stain in alcohol-soluble eosin staining solution for 3 min.
[0120] C. Dehydration and mounting: After staining, the sections are dehydrated by a series of conventional ethanol gradients, cleared with a clearing agent, and finally mounted with neutral resin.
[0121] D. Image acquisition and data analysis: The slides were observed and images were acquired using a Pannoramic 250 digital slide scanner produced by 3DHISTECH (Hungary). The images were imported into Caseviewer image analysis software, and the Linear measurement annotation tool in Annotation was selected. The thickness of the new epidermis, the thickness of the dermis (granulation tissue) and the full thickness of the wound were measured respectively. For each slide, five sites were randomly selected for each of the above three indicators for measurement and data were recorded. The measurement method referred to the previous method of the research group
[45] .
[0122] (3) Masson trichrome staining and collagen fiber detection
[0123] A. Dewaxing and Pretreatment: The sections were dewaxed to water using the same procedure as HE staining described above. The sections were then incubated overnight at room temperature in potassium dichromate solution, and the following day transferred to a 63 °C oven for 1 h of heat treatment.
[0124] B. Staining and Differentiation: The sections were stained in Ponceau S and Fuchsia solution for 10 min, and rinsed slightly with distilled water; then transferred to phosphomolybdic acid solution for a few seconds to 2 min. After confirming that the collagen fibers had faded under a microscope, they were counterstained in aniline blue solution for 2 min until the collagen fibers were stained.
[0125] C. Dehydration, mounting, and image acquisition: After conventional graded ethanol dehydration and clearing with a clearing agent, the sections were mounted with neutral resin. Pannoramic 250 digital slide scanners were used to acquire panoramic and partial (8×, 200×) microscopic images of the sections.
[0126] D. Area Measurement: The 200x magnification microscopic images were imported into the Image-Pro Plus 6.0 image analysis system (Media Cybernetics, USA) to extract and measure the expression area of blue collagen fibers within the field of view. The percentage of fiber tissue expression area was calculated using the formula (fiber tissue expression area / total field of view pixel area).
[0127] (4) Immunohistochemical staining and related indicator detection
[0128] A. Staining treatment: After routine dewaxing, hydration, and antigen retrieval of paraffin sections, primary antibodies (CD31, dilution 1:100; PCNA, dilution 1:800) were added and incubated. Secondary antibodies and chromogenic agents were added sequentially according to the instructions of the standard immunohistochemistry kit. DAB staining was performed, and hematoxylin counterstaining was applied to the cell nuclei. The sections were then routinely dehydrated, cleared, and mounted.
[0129] B. Image Acquisition and Analysis: Under the microscope, hematoxylin-stained cell nuclei appear blue, while DAB-stained positive expression areas appear brownish-yellow (CD31 is mainly located in the cytoplasm, and PCNA is mainly located in the nucleus). After reviewing the entire slide under low magnification, three 200x field-of-view images were randomly acquired. Image Pro Plus and Halo image analysis systems were used to calculate the number of microvessels and the percentage of positive expression area (% DAB Positive Tissue) in each field of view.
[0130] (5) Immunofluorescence staining
[0131] A. Dewaxing and Antigen Retrieval: Paraffin sections were sequentially dewaxed with dewaxing solution I, xylene II, and xylene III for 15 min each; then with anhydrous ethanol I, anhydrous ethanol II, 85% ethanol, and 75% ethanol for 5 min each, followed by washing with distilled water. The sections were then immersed in antigen retrieval solution and retrieval was performed using microwave method for 20 min. After natural cooling, the sections were washed three times with PBS for 5 min each time.
[0132] B. Blocking and Incubation: Sections were placed in 3% hydrogen peroxide solution and incubated at room temperature in the dark for 25 min. They were then washed three times with PBS on a decolorizing shaker for 5 min each time. The sections were then dried, and a histochemical pen was used to draw circles around the tissue periphery. Bovine serum was added, and the sections were blocked at room temperature for at least 30 min.
[0133] C. Antibody incubation: Add the prepared primary antibody mixture (CD68 1:200 mixed with CD80 1:50 or CD206 1:200 respectively), place the slide flat in a humidified chamber and incubate overnight at 4°C. The next day, wash three times with PBS for 5 min each time, then add the fluorescent secondary antibody mixture (HRP-labeled goat anti-rabbit 1:100 and CY3-labeled goat anti-mouse 1:200), incubate at 37°C in the dark for 30 min, and wash three times with PBS for 5 min each time.
[0134] D. Counterstaining and mounting: Add DAPI staining solution and incubate at room temperature for 10 min to counterstain cell nuclei. Wash three times with PBS and then add anti-fluorescence quenching mounting medium for mounting.
[0135] E. Image Acquisition and Analysis: Images were acquired using a fluorescence scanning imaging system. Under the microscope, DAPI-stained cell nuclei appeared blue, CD68-positive expression appeared green, and CD80 or CD206-positive expression appeared red (all mainly located in the cytoplasm). Three 200x fields of view were randomly selected from each slide and imported into Image-Pro Plus software for positive cell counting analysis.
[0136] 3.2 Experimental Results:
[0137] (1) Topical application of calcitriol and oral vitamin D promote epidermal regeneration in wounds.
[0138] HE staining quantitative analysis, such as Figure 8 As shown, Figure 8 Chinese: A1. Representative image of HE staining; A2. Epidermal thickness of wound at 4, 10 and 14 days post-injury; A3. Full-thickness thickness of wound at 4, 10 and 14 days post-injury.
[0139] from Figure 8 As can be seen, on days 4 and 14 post-injury, the thickness of newly formed epidermis in the diabetic control group was significantly lower than that in the healthy group (day 4, P = 0.0012; day 14, P < 0.0001). Compared with the diabetic control group, the thickness of newly formed epidermis in the topical calcitriol intervention group was significantly increased on days 4, 10, and 14 post-injury (day 4, P = 0.0426; day 10, P < 0.0001; day 14, P = 0.0002); the thickness of newly formed epidermis in the oral vitamin D group also increased significantly on days 4 and 10 post-injury (day 4, P < 0.0001; day 4, P < 0.0001), and although it still showed an increasing trend on day 14 post-injury, the difference was not statistically significant (P = 0.2217).
[0140] It is evident that topical application of calcitriol significantly prolongs the effective duration of epidermal regeneration in wounds compared to conventional oral vitamin D3.
[0141] (2) Topical application of calcitriol promotes thickening of the entire skin layer.
[0142] Full-thickness wound skin thickness analysis showed that on days 4, 10, and 14 post-wound, the full-thickness thickness in the diabetic control group was significantly lower than that in the healthy group (day 4, P < 0.0001; day 10, P < 0.0001; day 14, P = 0.0011). Compared with the diabetic control group, the full-thickness thickness in the topical calcitriol group was significantly increased in the early stages of wound healing (day 4, P = 0.0314; day 10, P < 0.0001). There was no significant difference in full-thickness thickness between the oral vitamin D group and the diabetic control group.
[0143] It is evident that topical application of calcitriol is significantly superior to conventional oral vitamin D3 in promoting the thickening of the entire skin layer.
[0144] 4. Effects of topical application of calcitriol and oral vitamin D on angiogenesis and proliferative activity in wounds.
[0145] To evaluate the effects of vitamin D-related interventions on wound angiogenesis and cell proliferation, this study used CD31 immunohistochemical staining to assess wound microvessel density and PCNA immunohistochemical staining to assess wound tissue cell proliferation.
[0146] 4.1 Experimental Methods:
[0147] The experimental groups are the same as those in "2" above.
[0148] For specific methods, please refer to section 3.1 above.
[0149] 4.2 Experimental Results:
[0150] (1) Increase the proportion of PCNA-positive cells in the wound.
[0151] PCNA immunohistochemical staining results as follows: Figure 9 As shown, Figure 9 Chinese: A1. Representative image of PCNA immunohistochemical staining; A2. Percentage of PCNA-positive cells in the wound at 4, 10, and 14 days post-wound. From Figure 9 As can be seen, on day 10 post-traumatic incision, the proportion of PCNA-positive cells in the diabetic control group was lower than that in the healthy group (P = 0.0004); the proportion in the topical calcitriol group was higher than that in the diabetic control group (P = 0.0086); while the proportion of PCNA-positive cells in the oral vitamin D group showed an increasing trend compared with the diabetic control group, the difference was not statistically significant (P = 0.0634). On day 14 post-traumatic incision, the proportion of PCNA-positive cells in the diabetic control group was lower than that in the healthy group (P = 0.0066), while the proportion in the topical calcitriol group was higher than that in the diabetic control group (P = 0.0014); there was no statistically significant difference between the oral vitamin D group and the diabetic control group (P = 0.1924).
[0152] It is evident that topical application of calcitriol significantly increases the proportion of PCNA-positive cells in the wound compared to conventional oral vitamin D3.
[0153] 5. Effects of topical application of calcitriol and oral vitamin D on macrophage polarization in wounds.
[0154] 5.1 Experimental Methods:
[0155] The experimental groups are the same as those in "2" above.
[0156] For specific methods, please refer to section 3.1 above.
[0157] 5.2 Experimental Results:
[0158] Topical application of calcitriol increases the number of M2 macrophages
[0159] The results of CD68 / CD206 double-positive cell analysis are as follows: Figure 10 As shown, Figure 10 A1. Representative image of CD68 and CD206 immunofluorescence double staining; A2. Number of M2 macrophages in the wound at 4, 10, and 14 days post-injury. Figure 10 The results showed that on days 4 and 10 post-injury, the number of M2 macrophages in the diabetic control group was significantly lower than that in the healthy group (day 4: P = 0.0002; day 10: P < 0.0001). While the number of M2 macrophages in the diabetic control group continued to decrease on day 14, the difference was not statistically significant (P = 0.0898). Compared with the diabetic control group, the number of M2 macrophages in the topical calcitriol group was higher on days 4, 10, and 14 post-injury (day 4: P = 0.0044; day 10: P = 0.0270; day 14: P = 0.0222). The number of M2 macrophages in the oral vitamin D group showed no significant difference from that in the diabetic control group at any of the observation stages post-injury. This indicates that topical application is more effective, and M2 macrophages promote wound healing.
[0160] It is evident that topical application of calcitriol can increase the number of M2 macrophages, while having almost no corresponding effect compared to conventional oral vitamin D3.
[0161] 6. Topical application of calcitriol combined with oral vitamin D increased VDR levels in wound tissue of diabetic rats.
[0162] To further evaluate whether vitamin D-related interventions affect VDR levels in wound tissues of diabetic rats, VDR levels in wound tissues of each group were measured on the day of wound initiation, and on days 10 and 14 post-initiation.
[0163] 6.1 Experimental Methods:
[0164] The experimental groups are the same as those in "2" above.
[0165] The specific method is as follows: Before testing, the frozen tissue sample is removed, an appropriate amount of tissue is weighed, and 9 times the volume of pre-cooled homogenizing medium is added. The sample is then thoroughly ground to prepare a 10% tissue homogenate. The homogenate is centrifuged at 4°C and 3500 rpm for 10 min, and the supernatant is used for subsequent testing. Simultaneously, BCA protein quantification is performed for subsequent result correction and statistical analysis. The entire process is conducted on ice.
[0166] The VDR level in wound tissue was detected using a rat Vitamin D3 Receptor (VDR) ELISA kit (CSB-EL025832RA, CUSABIO, China). The detection method was a double-antibody sandwich ELISA, and the experiment was strictly performed according to the kit instructions. Before the test, the tissue homogenate supernatant, standards, and relevant kit components were removed and equilibrated to room temperature. Standards, washing buffer, biotinylated antibody working solution, and HRP-avidin working solution were prepared according to the instructions, and standard wells, blank wells, and sample wells were set up. Each standard and sample was prepared in duplicate.
[0167] In a microplate pre-coated with VDR antibody, 100 μL of the corresponding concentration of standard was added to the standard wells, 100 μL of diluent was added to the blank wells, and 100 μL of the supernatant of the tissue homogenate to be tested was added to the sample wells. After coating, the plates were incubated at 37 ℃ for 2 h. After incubation, the liquid in the wells was discarded, and the plate was not washed. 100 μL of biotinylated antibody working solution was added to each well, and the plates were incubated at 37 ℃ for 1 h. Then, the liquid in the wells was discarded, and the plates were washed 3 times with washing buffer. After washing, 100 μL of HRP-avidin working solution was added to each well, and the plates were incubated at 37 ℃ for 1 h. The plates were then washed 5 times again, and 90 μL of TMB substrate solution was added to each well. The plates were incubated at 37 ℃ in the dark for 15–30 min, and finally, 50 μL of stop solution was added to each well to terminate the reaction.
[0168] Immediately after the reaction was terminated, the absorbance (OD) at 450 nm was measured using an ELISA reader. A four-parameter Logistic curve was fitted with the standard concentration on the x-axis and the OD value on the y-axis. The VDR concentration in the tissue homogenate was calculated based on the standard curve. The detection results were then combined with the protein concentration in the tissue homogenate and included in subsequent statistical analysis.
[0169] 6.2 Experimental Results:
[0170] The results are as follows Figure 11 As shown, from Figure 11As can be seen, on the day of wound aspiration, compared with the healthy group, the VDR levels in the wound tissue of the diabetic control group, the topical calcitriol intervention group, and the oral vitamin D group were significantly lower, with statistically significant differences (all P < 0.0001); however, there was no statistically significant difference among the three diabetic groups. On day 10 post-wound aspiration, the VDR level in the wound tissue of the diabetic control group was still lower than that of the healthy group (P < 0.0001). Compared with the diabetic control group, the VDR levels in the wound tissue of the topical calcitriol intervention group and the oral vitamin D group were significantly higher (all P < 0.0001), and both were higher than those of the healthy group (all P < 0.0001). There was no statistically significant difference between the topical calcitriol intervention group and the oral vitamin D group. On day 14 post-wound aspiration, the VDR level in the wound tissue of the diabetic control group was still significantly lower than that of the healthy group (P < 0.0001). Compared with the diabetic control group, the VDR levels in both the topical calcitriol intervention group and the oral vitamin D group were further increased (both P < 0.0001), and both were higher than those in the healthy group (both P < 0.0001). Furthermore, the VDR level in the topical calcitriol intervention group was higher than that in the oral vitamin D group, and the difference was statistically significant (P = 0.0346).
[0171] 7. Effects of topical application of calcitriol on the MAPK-ERK1 / 2 signaling pathway in rat wound tissue and HaCaT tissue after high glucose injury.
[0172] To further verify the expression levels of proteins related to the MAPK-ERK1 / 2 signaling pathway as indicated by RNA-seq analysis, skin tissue from the wound margins of rats in each group was collected on day 10 after wound initiation. Western blotting was used to detect the expression levels of related proteins such as VDR, ERK1 / 2, p90RSK, and EREG.
[0173] Experimental results:
[0174] The results are as follows Figure 12 As shown, Figure 12 Chinese image: Representative plot from Western blotting, B. Relative expression levels of MAPK-ERK1 / 2 signaling pathway-related proteins in wound tissue 10 days post-injury. Figure 12As can be seen, compared with the healthy group, the expression of VDR protein in the wound tissue of the diabetic control group was significantly reduced (P < 0.0001). Compared with the diabetic control group, the expression of VDR protein was significantly increased in both the topical calcitriol group (P < 0.0001) and the oral vitamin D3 group (P = 0.0080). The VDR level in the topical calcitriol group was not significantly different from that in the healthy group (P = 0.9898), while the oral vitamin D3 group was still lower than that in the healthy group (P = 0.0190). The VDR expression in the topical calcitriol group was higher than that in the oral vitamin D3 group (P = 0.0082). The results of p90RSK and its phosphorylation level showed that the p-p90RSK level was significantly reduced in the diabetic control group compared with the healthy group (P = 0.0028). Compared with the diabetic control group, the p-p90RSK levels in both the topical calcitriol group and the oral vitamin D3 group were significantly increased (topical calcitriol group: P < 0.0001; oral vitamin D3 group: P = 0.0005), and the p-p90RSK level in the topical calcitriol group was higher than that in the oral vitamin D3 group (P = 0.0249, which was statistically significant).
[0175] Example 7
[0176] Example 6 above demonstrated that topical application of calcitriol was more effective than oral administration. This example further demonstrates a comparison of the effects of topical injection of calcitriol and the hydrogelled calcitriol of the present invention. The following gel is the hydrogel prepared in Example 1 above.
[0177] This experiment further evaluated the in vivo healing-promoting effect of calcitriol-loaded GelMA hydrogel in a diabetic rat full-thickness skin wound model. The animal experiment was divided into four groups: a diabetic control group (CON), a topical calcitriol group (Calcitriol), a blank GelMA group (GM), and a GelMA combined with calcitriol group (GM-Calcitriol, i.e., the Example 1 group). The diabetic control group and the topical calcitriol group followed the every-other-day local intervention method described in Example 6; the GelMA-related groups (GM and GM-Calcitriol groups) were administered the drug once every 4 days, and the total dosage was adjusted by changing the single dose to maintain consistency with the topical calcitriol group, in order to preliminarily observe the effect of the GelMA hydrogel delivery system on diabetic wound repair under prolonged dosing intervals.
[0178] (1) Improve the wound healing rate in diabetic rats
[0179] The statistical results of wound healing rate are as follows: Figure 13 The above, Figure 13A. Representative images of wound conditions at different times; B. Wound healing rates at different times. Figure 13 The results showed that the wound healing rate in all groups gradually increased with the extension of post-wound time. On the second day after wound creation, compared with the diabetic control group, the wound healing rate of the topical calcitriol group and the GelMA combined with calcitriol group was significantly higher, with statistically significant differences (all P < 0.0001); there was no statistically significant difference between the blank GelMA group and the diabetic control group (P = 0.1359). Meanwhile, the wound healing rate of the topical calcitriol group was higher than that of the blank GelMA group (P = 0.0292), while there was no statistically significant difference between the topical calcitriol group and the GelMA combined with calcitriol group (P = 0.9938), suggesting that in the early stage of wound repair, GelMA loaded with calcitriol can achieve a healing-promoting effect similar to direct intervention with topical calcitriol.
[0180] On day 4 post-traumatic incision, the wound healing rates in all intervention groups were higher than those in the diabetic control group (all P < 0.0001). Specifically, the wound healing rate in the GelMA combined with calcitriol group was significantly higher than that in the local calcitriol group, the blank GelMA group, and the diabetic control group (compared to the Calcitriol group, P = 0.0002; compared to the GelMA group, P < 0.0001; compared to the CON group, P < 0.0001). This result suggests that in the early critical stage post-traumatic incision, calcitriol-loaded GelMA hydrogel has a more significant promoting effect on wound closure.
[0181] On day 6 post-debridement, the wound healing rates in the topical calcitriol group and the GelMA combined with calcitriol group remained higher than those in the diabetic control group (topical calcitriol group: P = 0.0006; GelMA combined with calcitriol group: P < 0.0001), while there was no statistically significant difference between the blank GelMA group and the diabetic control group (P = 0.8634). Simultaneously, the wound healing rate in the GelMA combined with calcitriol group was higher than that in the blank GelMA group (P < 0.0001), but there was no statistically significant difference compared to the topical calcitriol group (P = 0.2573). On day 8 post-debridement, the wound healing rate in the GelMA combined with calcitriol group remained significantly higher than that in the diabetic control group (P = 0.0022) and the blank GelMA group (P = 0.0122). Compared with the diabetic control group, the wound healing rate in the topical calcitriol group showed an increasing trend, but the difference was not statistically significant (P = 0.0531). These results indicate that GelMA combined with calcitriol can continuously improve the wound healing process in diabetic rats during the early and mid-stages of wound repair.
[0182] In summary, the GelMA combined with calcitriol group showed a higher wound healing rate than the diabetic control group on days 2, 4, 6, and 8 post-wound healing, and was also higher than the blank GelMA group on days 4, 6, and 8. Compared with the local calcitriol group, the GelMA combined with calcitriol group showed no statistically significant differences at any of the observation time points except for a higher wound healing rate on day 4, suggesting that the two groups have similar overall effects in promoting wound closure in diabetic patients. These results suggest that calcitriol-loaded GelMA hydrogel mainly promotes wound closure in the early and early-mid stages of diabetic wound repair.
[0183] (2) Improves wound tissue repair and promotes collagen deposition in diabetic rats
[0184] like Figure 14 As shown, Figure 14 In the figures, A1. Representative HE staining image; A2. Epidermal thickness of the wound at 4, 10, and 14 days post-injury; A3. Dermal thickness of the wound at 4, 10, and 14 days post-injury; A4. Full-thickness thickness of the wound at 4, 10, and 14 days post-injury. From A4, it can be seen that: Quantitative HE staining results showed that on day 4 post-injury, compared with the diabetic control group, the thickness of newly formed epidermis was increased in the local calcitriol group (P = 0.0341). Although the GelMA combined with calcitriol group showed an increasing trend, the difference was not statistically significant (P = 0.2336); there was no statistically significant difference between the blank GelMA group and the diabetic control group (P = 0.9974). By day 10 post-traumatic incision, the thickness of newly formed epidermis in both the topical calcitriol group and the GelMA combined with calcitriol group was significantly greater than that in the diabetic control group (Calcitriol group: P = 0.0001; GM-Calcitriol group: P = 0.0005), with no statistically significant difference between the two groups (P = 0.9905). Simultaneously, the thickness of newly formed epidermis in the GelMA combined with calcitriol group was significantly greater than that in the blank GelMA group (P < 0.0001), while there was no statistically significant difference between the two groups and the diabetic control group (P = 0.1938). By day 14 post-traumatic incision, there were no statistically significant differences in the thickness of newly formed epidermis among the groups.
[0185] Dermal thickness analysis showed that on day 4 post-arthritis, the dermal thickness of the local calcitriol group and the GelMA combined with calcitriol group was significantly greater than that of the diabetic control group (Calcitriol group: P = 0.0174; GM-Calcitriol group: P = 0.0114), while there was no statistically significant difference between the blank GelMA group and the diabetic control group (P = 0.4446). On day 10 post-arthritis, the differences in dermal thickness among the groups were not statistically significant. On day 14 post-arthritis, the dermal thickness of the blank GelMA group and the GelMA combined with calcitriol group was significantly greater than that of the diabetic control group (GM group: P = 0.0354; GM-Calcitriol group: P = 0.0309).
[0186] like Figure 15 As shown, A1. Representative image of Masson staining, A2. Percentage of collagen tissue in the wound at 4, 10 and 14 days post-injury. Figure 15 Analysis of the full-thickness wound thickness showed no statistically significant differences among the groups on day 4 post-surgery. On day 10 post-surgery, compared with the diabetic control group, the full-thickness wound thickness was increased in both the topical calcitriol group and the GelMA combined with calcitriol group (Calcitriol group: P = 0.0022; GM-Calcitriol group: P = 0.0243). On day 14 post-surgery, the full-thickness wound thickness was higher in both the blank GelMA group and the GelMA combined with calcitriol group than in the CON group (GM group: P = 0.0072; GM-Calcitriol group: P = 0.0003).
[0187] Overall, GelMA combined with calcitriol treatment can increase the thickness of newly formed epidermis, dermis, and full-thickness wound at different time points, suggesting that it has a promoting effect on the repair of tissue structure in diabetic wounds.
[0188] Masson staining results showed that on day 4 post-traumatic incision, the proportion of collagen fiber area in the wound was higher in the GelMA combined with calcitriol group than in the diabetic control group (P = 0.0195), while the other two groups showed no statistically significant difference compared to the diabetic control group. On day 10 post-traumatic incision, the proportion of collagen fiber area in all intervention groups was higher than that in the diabetic control group, and the GelMA combined with calcitriol group was higher than that in the local calcitriol group and the blank GelMA group (all P < 0.0001). On day 14 post-traumatic incision, the proportion of collagen fiber area in all intervention groups was also higher than that in the diabetic control group (Calcitriol group: P < 0.0001; GM group: P = 0.0031; GM-Calcitriol group: P < 0.0001), with the GelMA combined with calcitriol group being higher than that in the blank GelMA group (P < 0.0001), but there was no statistically significant difference between the intervention groups and the local calcitriol group (P = 0.1858). In summary, GelMA combined with calcitriol treatment can increase the level of collagen fiber deposition in diabetic wounds, suggesting that it has a promoting effect on wound matrix remodeling.
[0189] (3) Promotes angiogenesis and increases the proportion of proliferating cells in the wound of diabetic rats
[0190] like Figure 16 The above, Figure 16 Chinese: A1. Representative image of CD31 immunohistochemical staining; A2. Microvascular density of the wound at 4, 10 and 14 days post-injury. Figure 16 CD31 staining results showed that, on days 4, 10, and 14 post-injury, compared with the diabetic control group, the microvessel density of the wound was significantly increased in both the topical calcitriol group and the GelMA combined with calcitriol group (all P < 0.0001), and the microvessel density of the wound in the GelMA combined with calcitriol group was higher than that in the topical calcitriol group on days 10 and 14 post-injury (all P < 0.0001). Compared with the blank GelMA group, the microvessel density of the wound in the topical calcitriol group and the GelMA combined with calcitriol group also increased significantly on days 4, 10, and 14 post-injury (days 4, 10, and 14: Calcitriol group: P = 0.0195, P = 0.0008, P = 0.0001; GM-Calcitriol group: P = 0.0008, P < 0.0001, P < 0.0001). The microvessel density of the wound in the blank GelMA group was higher than that in the diabetic control group only on day 14 post-injury (P = 0.0007).
[0191] like Figure 17 As shown, Figure 17Chinese: A1. Representative image of PCNA immunohistochemical staining; A2. Percentage of PCNA-positive cells in the wound at 4, 10 and 14 days post-injury. Figure 17 PCNA staining results showed that on day 4 post-traumatic incision, the proportion of PCNA-positive cells in the GelMA combined with calcitriol group was higher than that in the diabetic control group (P = 0.0027), the local calcitriol group (P = 0.0460), and the blank GelMA group (P = 0.0051), while there was no statistically significant difference between the local calcitriol group, the blank GelMA group, and the diabetic control group. On day 10 post-injury, the proportion of PCNA-positive cells in the topical calcitriol group, the blank GelMA group, and the GelMA combined with calcitriol group was significantly higher than that in the diabetic control group (Calcitriol group: P = 0.0011; GM group: P = 0.0034; GM-Calcitriol group: P < 0.0001), and the proportion in the GelMA combined with calcitriol group was significantly higher than that in the topical calcitriol group and the blank GelMA group (GM-Calcitriol group: P = 0.0007; GM group: P = 0.0002). On day 14 post-injury, there was no statistically significant difference in the proportion of PCNA-positive cells among the groups. These results suggest that GelMA combined with calcitriol treatment can increase the microvascular density and the proportion of PCNA-positive cells in diabetic wounds, and promote angiogenesis and cell proliferation in wound tissue.
[0192] (4) Reduce the number of M1 macrophages and increase the number of M2 macrophages in the wound of diabetic rats.
[0193] like Figure 18 As shown, Figure 18 Chinese: A1. Representative image of CD68 and CD80 immunofluorescence double staining; A2. Number of M1 macrophages in the wound at 4, 10 and 14 days post-injury. Figure 18 Immunofluorescence double staining results for CD68 and CD80 showed that, compared with the diabetic control group, the number of M1 macrophages was significantly reduced in the local calcitriol group, the blank GelMA group, and the GelMA combined with calcitriol group on days 4, 10, and 14 post-traumatic incision (all P < 0.0001). Specifically, the number of M1 macrophages in the local calcitriol group and the GelMA combined with calcitriol group was significantly lower than that in the blank GelMA group (P < 0.0001 or P = 0.0001). However, the difference between the local calcitriol group and the GelMA combined with calcitriol group was not statistically significant (day 4: P = 0.8285; day 10: P = 0.0651; day 14: P = 0.5695).
[0194] As shown in 19, Figure 19 Chinese: A1. Representative image of CD68 and CD206 immunofluorescence double staining; A2. Number of M2 macrophages in the wound at 4, 10 and 14 days post-injury. Figure 19 Immunofluorescence double staining results for CD68 and CD206 showed that on day 4 post-traumatic injury, compared with the diabetic control group, the number of M2 macrophages was significantly increased in the local calcitriol group, the blank GelMA group, and the GelMA combined with calcitriol group (Calcitriol group: P < 0.0001; GM group: P = 0.0002; GM-Calcitriol group: P < 0.0001), with the GelMA combined with calcitriol group showing higher numbers than the local calcitriol group and the blank GelMA group (both P < 0.0001). On day 10 post-traumatic injury, the number of M2 macrophages in the local calcitriol group and the GelMA combined with calcitriol group was higher than that in the diabetic control group (both P < 0.0001), and the GelMA combined with calcitriol group showed a higher number than the local calcitriol group (P < 0.0001).
[0195] On day 14 post-traumatic incision, the number of M2 macrophages in the topical calcitriol group and the GelMA combined with calcitriol group was still higher than that in the diabetic control group (Calcitriol group: P = 0.0033; GM-Calcitriol group: P < 0.0001), and the GelMA combined with calcitriol group was still higher than that in the topical calcitriol group and the blank GelMA group (all P < 0.0001).
[0196] The results suggest that GelMA combined with calcitriol treatment can reduce the number of M1 macrophages and increase the number of M2 macrophages in diabetic wounds, indicating that it has a regulatory effect on the polarization state of macrophages in the wound. Compared with the local calcitriol group, the GelMA combined with calcitriol group showed a similar effect in reducing the number of M1 macrophages, but a more significant effect in increasing the number of M2 macrophages. The blank GelMA group also showed some improvement in the number of M1 macrophages and early M2 macrophages, suggesting that GelMA itself also has a certain regulatory effect on macrophage polarization in diabetic wounds.
[0197] In summary, the results indicate that GelMA combined with calcitriol treatment can improve skin thickness, collagen deposition, angiogenesis, cell proliferation, and macrophage polarization-related indicators in diabetic wounds at multiple stages, suggesting a sustained healing-promoting effect during tissue repair. Furthermore, compared to local calcitriol intervention, GelMA combined with calcitriol treatment showed similar or more significant improvements in most indicators.
[0198] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. The application of a calcitriol-functionalized injectable hydrogel in the preparation of a dressing for treating diabetic foot ulcers, characterized in that, The method for preparing the calcitriol-functionalized injectable hydrogel is as follows: (1) Dissolve the methacrylated macromolecule in pure water or phosphate buffer to obtain a methacrylated macromolecule solution, and then add the photoinitiator solution to the methacrylated macromolecule solution to obtain a gel precursor solution; (2) Dissolve calcitriol in a solubilizer to obtain calcitriol mother liquor; (3) Add the calcitriol mother liquor obtained in step (2) to the gel precursor solution obtained in step (1), mix evenly to obtain a mixture; form calcitriol functionalized hydrogel by ultraviolet light crosslinking; the concentration of calcitriol in the calcitriol functionalized hydrogel is 10 nmol / L to 500 nmol / L.
2. The application according to claim 1, characterized in that, In step (1), the macromolecules in the methacrylated macromolecules are selected from one of alginic acid, hyaluronic acid, chitosan, dextran, cellulose, gelatin and silk fibroin.
3. The application according to claim 2, characterized in that, The macromolecule in the methacrylated macromolecule is gelatin.
4. The application according to claim 1, characterized in that, In step (1), the concentration of the methacrylated macromolecular solution is 6 wt% to 20 wt%.
5. The application according to claim 1, characterized in that, In step (2), the solubilizer is selected from one of glycerol, triglycerides, propylene glycol, dimethyl sulfoxide, ethyl acetate and polyethylene glycol.
6. The application according to claim 1, characterized in that, In step (1), the photoinitiator is selected from 2-hydroxy-4'-(2-hydroxyethoxy)-2-methylphenylacetone and lithium phenyl-2,4,6-trimethylbenzoylphosphonate.
7. The application according to claim 1, characterized in that, In step (1), the mass of the photoinitiator added is 0.20% to 0.25% of the volume of the mixture.
8. The application according to claim 1, characterized in that, In step (3), the ultraviolet light has a wavelength of 365 nm to 405 nm and an intensity of 5 to 100 mW / cm. 2 The irradiation time is 60 s to 120 s.
Citation Information
Patent Citations
Wound coverings comprising vitamin d and related methods
US20180000980A1
Wound dressing compositions, especially for delivery of protease inhibitors
WO2006037606A2
